Skip to Content

'
Yasuhiro Oki, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit 0429
Unit Number: 429
Houston, TX 77030
Room Number: FC6.2012
Phone: 713-792-2860

Education & Training

Degree-Granting Education

1998 Faculty of Medicine, University of Tokyo, Tokyo, Japan, MD, Medicine

Postgraduate Training

7/2003-6/2006 Clinical Fellowship, Medical Oncology and Hematology, University of Texas, M.D. Anderson Cancer Center, Houston, TX, Robert A. Wolff
7/2000-6/2003 Clinical Residency, Internal Medicine, St. Luke's-Roosevelt Hospital Center, New York, NY, Ethan Fried
4/1998-3/2000 Clinical Residency, Internal Medicine, Toranomon Hospital, Tokyo, Japan, Yoshitomo Muto

Board Certifications

10/2008 American Board of Hematology
10/2006 American Board of Medical Oncology
8/2003 American Board of Internal Medicine

Experience/Service

Academic Appointments

Chief Physician (09/2007-08/2010), Aichi Cancer Center, Nagoya, Japan, 9/2006-8/2010

Administrative Appointments/Responsibilities

Quality Assessment Officer, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2015-present

Institutional Committee Activities

Member, Clinical Research Committee (CRC), 9/2013-8/2015

Honors and Awards

2009 Young Investigator Stipend Recipient, Pan Pacific Lymphoma Conference
2005-2006 Young Investigator Award, American Society of Clinical Oncology
2005 Best Research Presentation Award in Young Investigators Research Forum, Cancer - Related Symptoms Conference, Houston, TX
2003 Best Resident of the Year, St. Luke's - Roosevelt Hospital Center, Department of Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol. e-Pub 8/9/2016. PMID: 27502933.
2. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol 2(8):1065-9, 8/1/2016. e-Pub 5/26/2016. PMID: 27227654.
3. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. e-Pub 7/5/2016. PMID: 27378601.
4. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. e-Pub 7/22/2016. PMID: 27448187.
5. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, fludarabine and melphalan for reduced-intensity conditioning and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 22(7):1333-7, 7/2016. e-Pub 4/6/2016. PMID: 27064056.
6. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 27(7):1317-23, 7/2016. e-Pub 4/18/2016. PMID: 27091808.
7. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. e-Pub 6/28/2016. PMID: 27351173.
8. Cheah CY, Bröckelmann PJ, Chihara D, Moskowitz A, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA. Clinical characteristics and outcomes of patients with hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. Am J Hematol. e-Pub 5/24/2016. PMID: 27222367.
9. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. e-Pub 5/20/2016. PMID: 27203405.
10. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27(5):895-901, 5/2016. e-Pub 1/22/2016. PMID: 26802151.
11. Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RN. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol 40(5):676-88, 5/2016. e-Pub 2/11/2016. PMID: 26872013.
12. Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol 17(5):622-31, 5/2016. e-Pub 3/31/2016. PMID: 27049457.
13. Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol 17(3):389-400, 3/2016. e-Pub 2/10/2016. PMID: 26873565.
14. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk 16(3):122-8, 3/2016. e-Pub 12/22/2015. PMID: 26795083.
15. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, Rosa MD, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. e-Pub 11/27/2015. PMID: 26640039.
16. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, DiNapoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. e-Pub 11/2015. PMID: 26628470.
17. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171(4):463-70, 11/2015. e-Pub 7/27/2015. PMID: 26213141.
18. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic Stem Cell Transplantation in Patients With Cutaneous Lymphoma: Updated Results From a Single Institution. Ann Oncol. e-Pub 9/28/2015. PMID: 26416896.
19. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. e-Pub 9/11/2015. PMID: 26358140.
20. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. e-Pub 8/2015. PMID: 26260306.
21. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. e-Pub 6/10/2015. PMID: 26071868.
22. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood 125(21):3357-9, 5/21/2015. PMID: 25999447.
23. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-182, 5/2015. PMID: 25863764.
24. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by (18)Fluorodeoxyglucose Positron Emission Tomography. Int J Radiat Oncol Biol Phys 92(1):113-121, 5/2015. PMID: 25863759.
25. Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, Reed VK, Oki Y, Westin JR, Fayad LE, Medeiros LJ, Dabaja B. Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. e-Pub 3/2015. PMID: 25754633.
26. Peng J, Zuo Z, Fu B, Oki Y, Tang G, Goswami M, Priyanka P, Muzzafar T, Medeiros LJ, Luthra R, Wang SA. Chronic Myelomonocytic Leukemia with Nucleophosmin (NPM1) Mutation. Eur J Haematol. e-Pub 3/2015. PMID: 25809997.
27. Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Faham M, Younes A. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol. e-Pub 3/2015. PMID: 25818067.
28. Oki Y, Younes A, Knicerkbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. e-Pub 3/2015. PMID: 25820332.
29. Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. ICE (Ifosfamide, Carboplatin, Etoposide) with or without Bortezomib in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Randomized Phase II Trial. Leuk Lymphoma. e-Pub 3/2015. PMID: 25804933.
30. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Alma Rodriguez M. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 3/2015. e-Pub 9/28/2014. PMCID: PMC4344896.
31. Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. e-Pub 1/2015. PMID: 25573987.
32. Cheah CY, Oki Y, Westin JR, Turturro F. A clinician's guide to double hit lymphomas. Br J Haematol. e-Pub 12/2014. PMID: 25529575.
33. Hughes CL, Yorio JT, Kovitz C, Oki Y. Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barre syndrome: a case report. J Med Case Rep 8(1). e-Pub 12/2014. PMID: 25528252.
34. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 11/2014. e-Pub 10/2014. PMID: 25439689.
35. Chihara D, Oki Y. Brentuximab vedotin for treatment of systemic T-cell lymphoma. Expert Opin Biol Ther 14(10):1519-26, 10/2014. e-Pub 9/2014. PMID: 25200691.
36. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 167(2):177-84, 10/2014. e-Pub 7/2014. PMID: 25039868.
37. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 9/2014. e-Pub 6/2014. PMID: 24943107.
38. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 15(9):1019-26, 8/2014. e-Pub 7/2014. PMID: 25042202.
39. Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez A. Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation. Int J Radiat Oncol Biol Phys 89(2):384-91, 6/2014. e-Pub 4/2014. PMID: 24721592.
40. Oki Y. Use of panobinostat in patients with classical Hodgkin lymphoma. International Journal of Hematologic Oncology 3(3):203-210, 6/2014.
41. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell lymphomas with single agent brentuximab vedotin. Blood 123(20):3095-100, 5/2014. e-Pub 3/2014. PMID: 24652992.
42. Westin J, Oki Y, Fayad L. Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et al. Br J Haematol 165(1):146-7, 4/2014. e-Pub 12/2013. PMID: 24329994.
43. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 4/2014. e-Pub 1/2014. PMID: 24386943.
44. Leventaki V, Manning JT, Luthra R, Mehta P, Oki Y, Romaguera JE, Medeiros LJ, Vega F. Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. Hum Pathol 45(2):421-6, 2/2014. PMID: 24439229.
45. Oki Y, Buglio D, Zhang J, Ying Y, Zhou S, Sureda A, Ben-Yehuda D, Zinzani PL, Prince HM, Harrison SJ, Kirschbaum M, Johnston PB, Shen A, von Tresckow B, Younes A. Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer J 4:e236, 2014. e-Pub 8/2014. PMCID: PMC4219471.
46. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical Implications of PET-Negative Residual CT Masses after Chemotherapy for Diffuse Large B-Cell Lymphoma. Leuk Lymphoma 54(12):2631-8, 12/2013. e-Pub 5/2013. PMCID: PMC3827734.
47. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 19(24):6882-90, 12/2013. e-Pub 10/2013. PMID: 24097867.
48. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 12/2013. e-Pub 10/2013. PMID: 24117234.
49. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell Non-Hodgkin lymphoma. Br J Haematol 163(1):123-6, 10/2013. e-Pub 6/2013. PMID: 23795711.
50. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902-9, 9/2013. e-Pub 4/2013. PMID: 23545991.
51. Kato H, Yamamoto K, Oki Y, Ine S, Taji H, Chihara D, Kagami Y, Seto M, Morishima Y. Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas. Leukemia 27(8):1792, 8/2013. PMID: 23921999.
52. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 162(1):138-41, 7/2013. e-Pub 4/2013. PMID: 23590726.
53. Oki Y, Kondo Y, Yamamoto K, Ogura M, Kasai M, Kobayashi Y, Watanabe T, Uike N, Ohyashiki K, Okamoto S, Ohnishi K, Tomita A, Miyazaki Y, Tohyama K, Mukai HY, Hotta T, Tomonaga M. A phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. Cancer Sci 103(10):1839-47, 10/2012. e-Pub 9/2012. PMID: 22816487.
54. Oki Y, Younes A. Brentuximab vedotin in systemic T-cell lymphoma. Expert Opin Biol Ther 12(5):623-32, 5/2012. e-Pub 3/2012. PMID: 22428917.
55. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 5/2012. e-Pub 2/2012. PMCID: PMC3359733.
56. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171-2, 3/2012. PMID: 22383790.
57. Kato H, Yamamoto K, Taji H, Oki Y, Chihara D, Seto M, Kagami Y, Morishima Y. Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 11(6):483-9, 12/2011. PMID: 21978956.
58. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 12(13):1222-8, 12/2011. PMID: 22033282.
59. Oki Y, Copeland A, Romaguera J, Fayad L, Fanale M, de Castro Faria S, Jeffrey Medeiros L, Ivy P, Younes A. Clinical Experience with the Heat Shock Protein-90 inhibitor, Tanespimycin (17AAG), in Patients with Relapsed Lymphoma. Leuk Lymphoma. e-Pub 10/2011. PMID: 21988665.
60. Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, Morishima Y. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma. e-Pub 7/2011. PMID: 21745170.
61. Oki Y, Copeland A, Younes A. Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol 4(3):245-52, 6/2011. PMID: 21668391.
62. Chihara D, Oki Y, Onoda H, Taji H, Yamamoto K, Tamaki T, Morishima Y. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol 93(4):502-8, 4/2011. e-Pub 4/2011. PMID: 21512731.
63. Kato H, Kagami Y, Kodaira T, Oka S, Oki Y, Chihara D, Taji H, Yatabe Y, Nakamura T, Nakamura S, Seto M, Yamamoto K, Morishima Y. Nodal relapse after Helicobacter pylori eradication in a patient with primary localized gastric mucosa-associated lymphoid tissue lymphoma. Am J Gastroenterol 106(3):549-51, 3/2011. PMID: 21378774.
64. Estécio MR, Gallegos J, Vallot C, Castoro RJ, Chung W, Maegawa S, Oki Y, Kondo Y, Jelinek J, Shen L, Hartung H, Aplan PD, Czerniak BA, Liang S, Issa JP. Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res 20(10):1369-82, 10/2010. e-Pub 8/2010. PMCID: PMC2945186.
65. Kato H, Yamamoto K, Matsuo K, Oki Y, Taji H, Kuwatsuka Y, Seto M, Kagami Y, Morishima Y. Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. Ann Oncol 21(8):1699-705, 8/2010. e-Pub 2/2010. PMID: 20172906.
66. Oki Y, Younes A. Does rituximab have a place in treating classic hodgkin lymphoma? Curr Hematol Malig Rep 5(3):135-9, 7/2010. PMID: 20490723.
67. Chihara D, Oki Y, Ine S, Kato H, Onoda H, Taji H, Kagami Y, Yamamoto K, Morishima Y. Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan. Eur J Haematol 84(6):493-8, 6/2010. e-Pub 2/2010. PMID: 20148943.
68. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28(4):605-13, 2/2010. e-Pub 12/2009. PMCID: PMC2815995.
69. Chihara D, Kagami Y, Oki Y, Kato H, Onoda H, Ine S, Taji H, Yamamoto K, Morishima Y. R-CHOP therapy for MALT lymphoma of the rectum. Eur J Haematol 84(1):84-6, 1/2010. e-Pub 9/2009. PMID: 19737307.
70. Oki Y, Issa JP. Epigenetic mechanisms in AML - a target for therapy. Cancer Treat Res 145:19-40, 2010. PMID: 20306243.
71. Chihara D, Oki Y, Ine S, Yamamoto K, Kato H, Taji H, Kagami Y, Yatabe Y, Nakamura S, Morishima Y. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma 50(12):1999-2004, 12/2009. PMID: 19860627.
72. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(31):5213-8, 11/2009. e-Pub 9/2009. PMID: 19770379.
73. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 15(11):3881-8, 6/2009. e-Pub 5/2009. PMID: 19470736.
74. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol 81(6):448-53, 12/2008. e-Pub 8/2008. PMID: 18691256.
75. Oki Y, Kato H, Matsuo K, Kuwatsuka Y, Taji H, Yamamoto K, Kagami Y, Morishima Y. Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma 49(7):1345-51, 7/2008. PMID: 18452099.
76. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111(4):2382-4, 2/2008. e-Pub 11/2007. PMCID: PMC2234065.
77. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112(4):831-6, 2/2008. PMID: 18085611.
78. Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, Oshiro A, Tsujimura A, Yamamoto K, Morishima Y. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci 99(1):179-84, 1/2008. e-Pub 11/2007. PMID: 17991293.
79. Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A. Elevated serum BLyS levels in patients with non-Hodgkin lymphoma. Leuk Lymphoma 48(9):1869-71, 9/2007. PMID: 17786728.
80. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics 63(2):429-36, 6/2007. PMID: 17688495.
81. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109(5):899-906, 3/2007. PMID: 17236224.
82. Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes A. Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica 92(2):269-70, 2/2007. PMID: 17296586.
83. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastava PK, Younes A. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109(1):77-83, 1/2007. PMID: 17133412.
84. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52-7, 1/2007. e-Pub 8/2006. PMID: 16882708.
85. Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JP. Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res 66(10):5077-84, 5/2006. PMID: 16707430.
86. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 107(3):880-4, 2/2006. e-Pub 8/2005. PMID: 16123215.
87. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106(10):3370-3, 11/2005. e-Pub 7/2005. PMCID: PMC1895065.
88. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer 104(4):781-7, 8/2005. PMID: 15973667.

Invited Articles

1. Cheah CY, Oki Y, Fanale MA. Novel treatments for T-cell lymphoma. Am Soc Clin Oncol Educ Book 35:e468-78, 2015. PMID: 25993211.
2. Oki Y, Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma 49(5):883-9, 5/2008. PMID: 18452104.
3. Oki Y, Issa JP. Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. Int J Hematol 86(4):306-14, 11/2007. PMID: 18055336.
4. Oki Y, Aoki E, Issa JP. Decitabine--bedside to bench. Crit Rev Oncol Hematol 61(2):140-52, 2/2007. e-Pub 10/2006. PMID: 17023173.
5. Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica 91(8):1147-8, 8/2006. e-Pub 7/2006. PMID: 16870548.
6. Oki Y, Issa JP. Review: recent clinical trials in epigenetic therapy. Rev Recent Clin Trials 1(2):169-82, 5/2006. PMID: 18473969.
7. Oki Y, Younes A. Heat shock protein-based cancer vaccines. Expert Rev Vaccines 3(4):403-11, 8/2004. PMID: 15270645.

Editorials

1. Oki Y, Younes A. Endothelial progenitor cells in non-Hodgkin's lymphoma. Haematologica 92(4):433-4, 4/2007. PMID: 17488651.

Abstracts

1. Cheah C, Broeckelmann P, Moskowitz A, Engert A, Jerkeman M, El-Calaly T, Vose J, Villa D, Connors J, Feldman T, Chihara D, Pinnis C, Milgron S, Sabaja B, Oki Y, Fanale M. Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An Internationl Multicenter Collaboration. Blood (2015 ASH Annual Meeting 126(123), 12/2015.
2. Nieto Y, Valdez B, Thall P, Wei W, Jones R, Hosing C, Ahmed S, Popat U, Shpall E, Qazilbash M, Gulbis A, Anderlni P, Shah N, Bashir Q, Alousi A, Oki Y, Hagemeister F, Champlin R, Andersson B. Double Epigentic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
3. Fanale M, Wang Z, Ma W, Oki Y, Hagemeister F, Fayad L, Fowelr N, Romaguera J, Shah N, Chuang H, Lei F, Horowitz S, Chihara D, Wesson E, Hutto T, Ruben C, Samaniego F, Muzzafar T, Piekarz R, Davis RE. Gene Expression Profiling for Milecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
4. Chihara D, Oki Y, Westin J, Nastoupil L, Fayad L, Samaniego F, Wesson E, Ruben Charnelle, Horowitz S, Feng L, Garg N, Ahmed S, Khouri I, Hosing C, Romaguera J, Fowler N, Fanale M. HIgh Response Rate of Romidepsin in Combination wtih ICU (Ifosfamide, Carboplatin and Etoposide) in Patients with RElapsed or Refractory Peripheral T-Cell Lyphoma: Updates of Phase I Trial. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
5. Wang Y, Wagner-Bartak N, Zhou S, Fowler N, DeLaRosa M, Zhao D, Romaguera J, Neelapu S, Hagemeister F, Fanale M, Oki Y, Shah J, Thomas S, Hosing C, Zhang L, Badillo M, Chen W, Cai, Q, Zou D, Champlin R, Fayad L, Lee HJ, Wang M. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
6. Chihara D, Ahmed M, Oki Y, Westin J, Hagemeister F, Romaguera J, Fanale M, Lee HJ, Turturro F, Samaniego F, Neelapu S, Rodriguez A, Fowler N, Wang M, Fayad L, Davis RE, Nastoupil. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
7. Brammer J, Poon M, Koh L, Caimi P, DeLima M, Ledesma C, Dibb W, Khouri I, Oki Y, Fanale M, Champlin R, Maziarz R, Hosing C. Multi-Center Study of Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Extra-Nodal Natural Killer/T-Cell Lymphoma, Nasal Type (ENKL). Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
8. Younes A, Berdeja J, Patel M, Kelly K, Flinn I, Gerecitano J, Neelpau S, Copeland A, Akins A, Clancy M, Ma A, Sun K, Tien S, Wang J, Viner J, Oki Y. Phase 1 Trial Testing Single Agent CUDC-907, A Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and P13K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
9. Nieto Y, Bassett R, Anderlini P, Hosing C, Alousi A, Popat U, Andersan B, Valdez B, Shpall E, Ahmed S, Qazilbash M, Guillermo M, Oki Y, Fanale M, Hagemeister F, Dabaja B, Pinnix C, Milgram S, Tewari P, Champlin R, Jones R. Prospective Phase 2 Trial of High Dose Gemcitabine/Busulfan/Melphalan (Gen/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
10. Johnston P, Cashen A, Nikolinakos P, Beaven A, Barta S, Bhat G, Song t, Choi M, Allen L, deVos S, Oki Y, Deng C, Foss F. Safe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 Trial. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
11. Ahmed M, Oki Y, Noorani M, Nastoupil L, Fayad L, Hagemeister F, Rodriguez A, Davis RE, Westin J. The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (CLBCL) Treated with Standard or Liposomal Chemotherapies. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
12. Chihara D, Fanale M, Noorani M, Westin J, Nastoupil L, Hagemeister F, Fayad L, Romaguera J, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda R, Hosing C, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
13. Chihara D, Fanale M, Noorani M, Westin J, Nastoupil L, Hagemeister F, Fayad L, Romaguera J, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda R, Hosing C, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
14. Oki Y, Neelapu S, Fanael M, Kwak L, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Fahan M, Younes A. A sequence Level Analysis of Hodgkin Lymphoma Clonotypes Detected in Peripheral Blood Using a Next-Generation Sequencing Approach. Blood (ASH Annual Meeting 2014) 124(21), 12/2014.
15. Oki Y, Fanale M, Romaguera JE, Fayad L, Fowler N, Copeland AAR, Samaniego F, Kwak LW, Neelapu S, Want M, Feng L, Younes A. Phase II Study of an AKT Inhibitor MK2206 in Patients with Relapsed or Refractory Lymphoma. Blood (ASH Annual Meeting 2014) 124(21), 12/2014.
16. Ahmed M, Fowler N, Ma L, Mansoor N, Lee ST, Fen L, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin J, Nastoupil L, Kwak L, David RE, Neelapu S. R-Bendamustine vs. R-CHOP as Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Blood (ASH Annual Meeting 2014) 124(21), 12/2014.
17. Ahmed M, Fowler N, Ma L, Noorani M, Phasalkar K, Hagemeister F, Romaguera J, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin J, Kwak L, Nastoupil L, Cheah C, Feng L, Rohren E, Davis R, Neelapu S. SUVmax on Pre-Treatment FDG PET Scan is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Therapy. Blood (ASH Annual Meeting 2014) 124(21), 12/2014.
18. Oki, Y, Fanale, MA, Westin, JR, Fowler, N, Neelapu, SS, Hagemeister, FB, Rodriguez, MA, Younes, A. A Phase I Study Of Panobinostat In Combination With ICE (Ifosfamide, Carboplatin and Etoposide) In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (cHL). Blood (ASH 2013 Annual Meeting Abstract) 122(21):252, 12/2013.
19. Younes, A, Flinn, I, Berdeja, J, Friedberg, JW, Casulo, C, Thieblemont, C, Morschhauser, F, Westin, JR, Seetharam, S, Hellemans, P, Smit, H, de Vries, R, Dauphinee, E, Badamo-Dotzis, J, Fourneau, N, Oki, Y. Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell Non-Hodgkin’s Lymphoma (NHL). Blood (ASH Annual Meeting Abstract - Oral Session) 122(21):852, 12/2013.
20. Oki, Y, Neelapu, SS, Fanale, MA, Kwak, LW, Fayad, LE, Rodriguez, A, Wallace, M, Carlton, V, Kong, K, Faham, M, Younes, Y. Detection Of Classical Hodgkin Lymphoma In Peripheral Blood Using High-Throughput Sequencing Assay. Blood (ASH Annual Meeting Abstract - Oral) 122(21):627, 12/2013.
21. Oki, Y, Noorani, M, Davis, RE, Neelapu, SS, Rodriguez, A, Hagemeister, FB, Fowler, N, Wang, M, Fanale, MA, Samaniego, F, Dabaja, BS, Pinnix, C, Kwak, LW, Romaguera, JE, Khouri, I, Westin, JR, Fayad, LE. Double Hit Lymphoma: M.D. Anderson Experience. Blood (ASH Annual Meeting Poster) 122(21):1776, 12/2013.
22. Jacobsen, ED, Advani, RH, Oki, Y, Sharman, JP, Horwitz, SM, Forero-Torres, A, O'Connor, OA, Shustov, AR, Siddiqi, T, Grove, LE, Bartlett, NL. A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results. Blood (ASH Annual Meeting Abstract) 120(21) (#2746), 12/2012.
23. Khouri, IF, Rima, SM, Turturro, F, Korbling, M, Ledesma, C, Rondon, G, Alousi, AM, Anderlini, P, Bashir, Q, Ciurea, SO, Hosing, CM, Popat UR, Charafeddine, Y, Oki, Y, Fayad, LE, Champlin, RE. Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstract) 120(21) (#4157), 12/2012.
24. Oki, Y, Faham, M, Carlton, V, Neelapu, SS, Younes, A. Detection of Diffuse Large B-Cell Lymphoma in Peripheral Blood Using High-Throughput Sequencing Assay. Blood (ASH Annual Meeting Abstract) 120(21) (#2666), 12/2012.
25. Kato, H, Kodaira, T, Yamamoto, K, Oshima, Y, Oki, Y, Tachibana, H, Taji, H, Murakami, S, Hirano, D, Tomita, N, Yatabe, Y, Nakamura, S, Tomohiro K. Durable Local Disease Control and Survival in Patients with Limited-Stage Diffuse Large B-Cell Lymphoma Receiving Involved-Node Radiation Therapy Plus Short-Course R-CHOP or CHOP Chemotherapy: Involved-Node Versus Involved-Field Radiation Therapy. Blood (ASH Annual Meeting Abstract) 120(21) (#3664), 12/2012.
26. Fowler, NH, Neelapu, SS, Hagemeister, FB, McLaughlin, P, Kwak, LW, Romaguera, JE, Fanale, MA, Fayad, LE, Orlowski, RZ, Wang, M, Turturro, F, Oki, Y, Lacerte, LC, Samaniego, F. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Blood (ASH Annual Meeting Abstract) 120(21) (#901), 12/2012.
27. Oki, Y, Westin, JR, Fowler, NH, Neelapu, SS, Hagemeister, FB, McLaughlin, P, Kwak, LW, Romaguera, JE, Fanale, MA, Younes, A, Rodriguez, MA, Orlowski, RZ, Wang, M, Ouzounian, S. Samaniego, F, Fayad, L. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood (ASH Annual Meeting Abstracts) 120(21):377 (#3707), 12/2012.
28. Takahashi, K, Sivina, M, Oki, Y, Fayad, LE, Neelapu, SS, Kwak, LW, Xiao, L, Huang, X, Fu, K, Chan, WC, Vose, JM, Kantarjian, HM, Keating, M. Burger, JA,. Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma. Blood (ASH Annual Meeting Abstract) 120(21) (#2709), 12/2012.
29. Oki Y,Chuang H,Chasen B, Pan T, Fanale MA, Dabaja BS, Fowler NH, Romaguera JE, Fayad LE, Hagemeister FB , Rodriguez A, Neelapu SS, Samaniego F, Kwak LW, Younes A. The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstract) 120(21):1529 (#1529), 12/2012.
30. Advani, R, Oki, Y, Shustov, AR, Grove, LE, Bartlett, N. Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study. J Clin Oncol (2012 ASCO Annual Meeting):suppl; abstr 8070, 2012.
31. Oki, Y, Matsuo, K, Kato, H, Yamamoto, K, Kagami, Y, Morishima, Y. Prognostic Value of Serum Soluble IL2 Receptor (sIL2R) Level in Patients with Diffuse Large B Cell Lymphoma (DLBCL), Treated with CHOP or R-CHOP Based Therapy. Blood (ASH Annual Meeting Abstracts) 110(11):1569, 2007.
32. Oki, Y, Jelinek, J, Kantarjian, HM, Issa, JJ. Hypomethylation Induction and Molecular Response after Decitabine Therapy in Chronic Myelomonocytic Leukemia (CMML). Blood (ASH Annual Meeting Abstracts) 108(11):2322, 11/2006.

Letters to the Editor

1. Oki Y, Copeland A, Hagemeister F, Fayad L, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171 - 2, 3/2012.
2. Oki Y, Kishi Y, Kami M. Philadelphia chromosome-positive acute lymphoblastic leukemia in children. N Engl J Med 343(14):1043, 10/2000.
3. Oki Y, Kami M, Muto Y. Long-term survival after bone marrow transplantation. N Engl J Med 341(18):1394; author reply 1395, 10/1999. PMID: 10577087.

Grant & Contract Support

Title: Phase I Dose Finding Study of pralatrexate plus cyclophosphamide/Vincristine/Doxorubicin/Pednisone (CHOP) Regimen (Fol-CHOP) For Treatment of Patients with Peripheral T-cell Lymphoma (PTCL).
Funding Source: Spectrum Pharmaceuticals
Role: Principal Investigator
Duration: 2014 - present
 
Title: Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma and MyD88 L265P Mutation, 2014-0705
Funding Source: Idera Pharmaceuticals
Role: Principal Investigator
Duration: 2014 - present
 
Title: A Phase 2 open label study to investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive extranodal NK/T-cell lymphoma (ENKTCL)
Funding Source: Cellmedica
Role: Principal Investigator
Duration: 2013 - present
 
Title: Phase I Open Label, Multi-center, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, a PI3K and HDAC Inhibitor, in Subjects with Refractory or Relapsed Lymphoma or Multiple Myeloma.
Funding Source: Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center
Role: Principal Investigator-MDACC
Duration: 2013 - present
 
Title: Epigenetic analysis of non-Hodgkin lymphoma.
Funding Source: Japan Society for the Promotion of Science
Role: Principal Investigator
Duration: 2008 - 2009

Last updated: 8/24/2016